The Optispan Podcast with Matt Kaeberlein

A recent study suggests metformin may slow biological aging in male primates, sparking intriguing discussions. The hosts critically analyze the research methodology and the importance of thorough data presentation. They delve into the evolving views on metformin’s role in longevity and emphasize the need for more rigorous studies to avoid overinterpretation. The potential geroprotective effects on various tissues are highlighted, alongside concerns about research transparency and incentives within the scientific community.

Subscribe to our channel: https://www.youtube.com/@optispan We recently came across a study published in the European Journal of Nutrition that examined the relationship between plant and animal protein intake and measures of biological aging. The study, which uses data from the UK Biobank, a long-term database of biological data from half a million participants in the United Kingdom, found that a higher plant protein intake correlates inversely with biological aging. Matt takes us through the study and gives us his take on the results and potential explanations for them as well as on the validity of the biological age measures used, the complexities of nutrition research, and core principles of healthy eating. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/ Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this podcast I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Subscribe to our channel: https://www.youtube.com/@optispan More about the Dog Aging Project: https://dogagingproject.org/ The Dog Aging Institute: https://dogaginginstitute.org Enroll your dog in the Dog Aging Project: https://redcap.dogagingproject.org/surveys/?s=DYYDHK8HAP We get lots of feedback and questions about the Dog Aging Project (DAP) from viewers, so we wanted to provide an update about how the project is going as well as some context. In this episode, Matt dives into the project's winding 10-year history, which includes navigating the vagaries of government funding, handling skepticism from fellow academics, and managing clinical trial enrollment in the midst of a global pandemic. He provides a candid peek into the logistical coordination, interdisciplinary collaboration, and leadership required to run a large-scale, ambitious scientific project such as the DAP, and the necessity of articulating clear and compelling goals that can rally support from both the scientific community and funding bodies. The DAP is a study of canine health and longevity aimed at understanding how dogs—and, eventually, humans—age. The project has two broad goals: to help us understand the biology of aging, and to enable us to do something about it. A third goal that often goes unmentioned, but is (to some) no less important, is to give us more time with furry friends who often become part of the family. The DAP has grown to become the world's largest study of aging. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/ Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this podcast I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Discover the four essential pillars of health that can transform your well-being. Dive into how eating, moving, sleeping, and connecting with others impact aging. Gain practical tips to identify your weakest area and take actionable steps to enhance your healthspan. Matt emphasizes the importance of self-assessment and using diagnostics for better long-term health outcomes.

Discover the latest findings from the PEARL trial, a groundbreaking study on rapamycin's potential to combat aging. Explore innovative dosing strategies, including an eight-on, four-off regimen, aimed at maximizing longevity. Delve into the differences between rapamycin and Everolimus, as well as the nuances in their effects on aging. Unpack the complexities and costs of conducting longevity trials, and learn why functional measures might be more effective than direct aging reversal metrics. Get ready for a captivating deep dive into the science of aging!

Mike Mutzel, an expert in supplements and cholesterol, shares his insights on optimizing healthspan. He explores the significance of vitamin D, advocating for personalized supplementation. The conversation dives into the complexities of cholesterol, challenging traditional views on LDL levels and longevity. Mike also discusses the importance of body composition tools, heavy metal testing, and lifestyle changes to mitigate health risks. Additionally, he highlights the role of social connections in reversing diabetes and enhancing overall wellness.

Subscribe to our channel: https://www.youtube.com/@optispan Check out the paper: https://www.nature.com/articles/s41586-024-07701-9.pdf Related episodes: The Benefits of Protein Restriction, How Protein Affects Hormones & FGF21: https://youtu.be/Nf1GhkAFiWY A recent paper demonstrating that injecting older mice with an anti-IL-11 drug extended their median lifespan made a splash in the geroscience community this summer. IL-11 is a proinflammatory cytokine that plays a role in regulating various biological processes, including hematopoiesis (the production of blood cells), bone health and remodeling, and tissue repair. Meanwhile, cytokines act as messengers between cells, helping to regulate immune responses, inflammation, and the production of blood cells. In excess or when dysregulated, cytokines can contribute to chronic inflammation and autoimmune diseases. In this episode, Matt discusses the role IL-11 plays in the body, the ERK, AMPK, and mTOR pathways, genetic and pharmacological models of IL-11 reduction, and more. He goes over the paper's claims and provides his take on whether this finding is a game-changer in the longevity field as well as on what further questions he'd like to see answered in follow-up studies. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/ Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this podcast I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Subscribe to our channel: https://www.youtube.com/@optispan Check out paper #1 on IL-11 signaling: https://www.nature.com/articles/s41586-024-07701-9.pdf Check out paper #2 on combination trametinib/rapamycin treatment: https://www.biorxiv.org/content/biorxiv/early/2024/07/25/2024.07.25.605097.full.pdf Related episodes: An introduction to the study of RAPAMYCIN: https://www.youtube.com/watch?v=czx_-DqnnrQ&t=1s In this episode, Matt discusses two recent mouse lifespan studies: one focused on inhibiting IL-11 signaling, and one focused on combined trametinib and rapamycin treatment. IL-11, or Interleukin-11, is a protein that plays an important role in modulating inflammation and healing, while trametinib is an FDA-approved drug that targets certain cancers, particularly melanoma. You can find extensive discussion of rapamycin in our R-Files series linked above. Matt explains the "900-day rule" for evaluating mouse lifespan studies such as these two, and provides his take on whether these results are game-changers for the geroscience field as well as whether we should consider these interventions for human use at this time. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/ Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this podcast I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!

Scott Carney, an investigative journalist and author, challenges David Sinclair's longevity claims, sparking an intriguing discussion on the nuances of scientific integrity and commercial influences in aging research. The dialogue touches on the skepticism surrounding aging treatments like resveratrol and NMN, emphasizing the need for rigorous evaluation over sensationalism. They also reflect on personal dynamics within the scientific community, highlighting the importance of separating emotions from objective scrutiny in the quest for lifespan extension.

The podcast dives into the fascinating study on nicotinamide mononucleotide (NMN) and its potential to boost VO2 max in amateur runners. The hosts critically assess the credibility of research from lesser-known institutions and highlight regulatory challenges NMN faces in the market. They also dissect the study's design, focusing on its methodological limitations, including small sample sizes and absence of female participants. While improvements were noted, the overall impact on endurance performance remains unclear, prompting cautious enthusiasm.